| 000 | 01556 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250517143022.0 | ||
| 264 | 0 | _c20171019 | |
| 008 | 201710s 0 0 eng d | ||
| 022 | _a1558-822X | ||
| 024 | 7 |
_a10.1007/s11899-017-0374-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBashir, Qaiser | |
| 245 | 0 | 0 |
_aAllogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work. _h[electronic resource] |
| 260 |
_bCurrent hematologic malignancy reports _c04 2017 |
||
| 300 |
_a126-135 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xetiology |
| 650 | 0 | 4 |
_aGraft vs Tumor Effect _ximmunology |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKiller Cells, Natural _ximmunology |
| 650 | 0 | 4 | _aMaintenance Chemotherapy |
| 650 | 0 | 4 |
_aMultiple Myeloma _xdiagnosis |
| 650 | 0 | 4 |
_aNeoplasm, Residual _xpathology |
| 650 | 0 | 4 |
_aReceptors, KIR _xmetabolism |
| 650 | 0 | 4 | _aRetreatment |
| 650 | 0 | 4 | _aTissue Donors |
| 650 | 0 | 4 |
_aTransplantation Conditioning _xadverse effects |
| 650 | 0 | 4 | _aTransplantation, Autologous |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 650 | 0 | 4 | _aTransplantation, Isogeneic |
| 700 | 1 | _aQazilbash, Muzaffar H | |
| 773 | 0 |
_tCurrent hematologic malignancy reports _gvol. 12 _gno. 2 _gp. 126-135 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s11899-017-0374-1 _zAvailable from publisher's website |
| 999 |
_c26960487 _d26960487 |
||